DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Category Uncategorized

Travere Therapeutics ( $TVTX ) after FILSPARI’s FDA approval in FSGS

TVTX Approved

Travere Therapeutics did not just clear another FDA box on April 13, 2026. It materially changed the shape of its equity story. FILSPARI, already commercial in IgA nephropathy, now has a second FDA-approved kidney disease indication: reduction of proteinuria in adults and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis, or FSGS, without nephrotic syndrome. That is a narrower label than the most aggressive bulls had once hoped for, but it is still a real commercial approval, not a consolation prize, and it makes FILSPARI the first and only FDA-approved medicine for FSGS.

IOVANCE BIOTHERAPEUTICS (NASDAQ: $IOVA) March 27 2026 DD

iova march 27

Iovance enters the next stretch in a very different place than where the bull case used to live. The stock still has a powerful story behind it: AMTAGVI is already commercial, the TIL platform is no longer theoretical, and the company is trying to push that proof into larger and commercially more meaningful opportunities such as NSCLC. But this is also a company that the market punished hard when execution, European regulatory ambition and financing optics stopped matching the earlier narrative. That history matters because it explains why each new positive data point now has to pass a tougher test with investors.

Kodiak Sciences ( $KOD ): GLOW2 hits cleanly, Zenkuda clears the second major diabetic retinopathy hurdle

Positive GLOW2 topline data do more than add one more green headline to the tape. They materially strengthen the diabetic retinopathy package around Zenkuda, reduce the “one-study wonder” risk left after GLOW1, and push the KOD debate toward the next question that really matters: how much value the market should assign to a program that now looks BLA-ready across multiple retinal settings, while still carrying the memory of earlier setbacks and the need to deliver again in DAYBREAK.